ocrelizumab
ocrelizumab: 6 clinical trials tracked.
ocrelizumab evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about ocrelizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Clinical Trial Registry Records (6)
REMIBRUTINIB: EVALUATION OF FLUID AND INFLAMMATORY NEUROIMAGING ENDPOINTS IN MULTIPLE SCLEROSIS (REDEFINE-MS)
Primary endpoint: Change in Microglial Activity Measured by [11C]-DPA-713 PET
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
Primary endpoint: Proportion of Patients with Wearing-Off
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib
Primary endpoint: Annualized rate of new or enlarging T2 lesions_Core Part
A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
Primary endpoint: Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)
Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Primary endpoint: Number of Major Congenital Malformations (MCMs)
A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Primary endpoint: Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)